ArticleAging2019
Apigenin inhibits growth and migration of fibroblasts by suppressing FAK signaling.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Retraction of: miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN.Aging · 2024Article
- Characterization and Physiological Differences of Two Primary Cultures of Human Normal and Hypertrophic Scar Dermal Fibroblasts: A Pilot Study.Biomedicines · 2024Article
- Retraction of: Sulfated polysaccharide ofAging · 2024Article
- On the Value of In Vitro Cell Systems for Mechanobiology from the Perspective of Yes-Associated Protein/Transcriptional Co-Activator with a PDZ-Binding Motif and Focal Adhesion Kinase and Their Involvement in Wound Healing, Cancer, Aging, and Senescence.International journal of molecular sciences · 2023Review
- Pharmacological Properties of 4', 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways.Molecules (Basel, Switzerland) · 2022Review
- The potential of functionalized dressing releasing flavonoids facilitates scar-free healing.Frontiers in medicine · 2022Review
- Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment.Cancer cell international · 2021Review
- Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-PPAR research · 2021Article
- Recent insights into the biological functions of apigenin.EXCLI journal · 2020Article
Corrections and comments
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The naturally occurring compound apigenin has many biological effects, including anti-inflammatory, antioxidative and anticancer effects. Although hypertrophic scar formation is a common surgical complication, there is still no good treatment for it. In the present study, we examined the effect of apigenin on hypertrophic scar. After isolating fibroblasts from human hypertrophic scars, we assess the effects of apigenin on fibroblast cell survival, apoptosis and migration. The results showed that apigenin dose-dependently inhibited the growth and migration of hypertrophic scar fibroblasts. By inhibiting FAK kinase activity and FAK phosphorylation, apigenin also inhibited activation of the FAK signaling pathway. Apigenin thus appears to inhibit the growth and migration of hypertrophic scar fibroblasts by inhibiting FAK signaling. This suggests apigenin could potentially provide a new option for the treatment of hypertrophic scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.